From a pharmacological perspective, with the advancement of specific HMOX1 inducers and CO-releasing molecules [5,14,51,52,53,54], it is important to assess the safety and effectiveness of these agents in DLE patients, both through systemic and local administration. This evidence concerns the gene HMOX1 and discoid lupus erythematosus.